摘要
凝血因子Xa是内源性凝血系统和外源性凝血系统的交汇点。针对凝血因子Xa的新型抗凝药物具有疗效显著、使用方便、不需实验室监测、出血不良反应少等优点。间接凝血因子Xa抑制药璜达肝素、艾屈肝素、idrabiotaparinux、SR123781和直接凝血因子Xa抑制药利伐沙班、apixaban、betrixaban、edoxaban、eribaxaban、LY517717、YM150、letaxaban、奥米沙班是目前研究较多的药物。
Factor Xa is located at the intersection of the intrinsic and extrinsic pathways in the coagulation cascade. The newer anticoagulant drugs targeting factor Xa have the advantage of good efficacy, more convenience, no laboratory monitoring, and less bleeding side effect. Indirect factor Xa inhibitor fondaparinux, idraparinux, idrabiotaparinux, SR123781 and direct factor Xa inhibitor rivaroxaban, apixaban, betrixaban, edoxaban, eribaxaban, LY517717, YM150, letaxaban, otamixaban are the more studied drugs nowadays.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2012年第9期505-510,共6页
Chinese Journal of New Drugs and Clinical Remedies
关键词
因子Xa
抗凝药
血栓栓塞
静脉血栓形成
factor Xa
anticoagulants
thromboembolism events
venous thrombosis
